Pfizer withdrew Oxbryta (voxelotor), a conditionally approved oral therapy for SCD, saying its benefits don't outweigh risks.
A Nigerian hematologist will pursue a PhD in health policy at the University of Tennessee Health Science Center to help advance her work on programs for sickle cell disease (SCD) in her home country.
I’ve discussed before how infections have been a menace to managing sickle cell disease. I’ve also explained how sickle cell patients are more susceptible to infections because of our compromised ...